Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey
Internal Medicine Journal · 2025
DOI: 10.1111/imj.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Lisa M Raven und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Insulin, Hypoglycemic Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Diabetic ketoacidosis (DKA) is a hyperglycaemic emergency, and insulin administration is highly protocolised with either variable‐ or fixed‐rate intravenous infusions. There are limited data supporting superiority of one regimen over another; however, international guidelines recommend fixed‐rate infusions.
Aim
To characterise DKA management protocols used in Australian hospitals.
Methods
An online survey of Australian endocrinologists and intensive care physicians between May and July 2024. The main outcome measure was the proportion of respondents using a fixed or variable rate, or combination, for the management of DKA. Secondary outcomes were the location of management, definition of resolution and intravenous fluid specification.
Results
There were 31 respondents from individual hospitals around Australia, with 84% of endocrinologists and 84% from metropolitan hospitals. There was wide variation in insulin regimens including fixed ( n = 12), variable ( n = 14) and combination ( n = 5) infusion protocols. Most (23/30, 77%) respondents had worked at another hospital that had a different DKA management protocol. There was a 50% split ( n = 14 each) in personal preference for fixed‐ or variable‐rate infusion, with three respondents having no preference. Most (21/31, 68%) protocols defined resolution of DKA. Blood pH (15/21, 71%) and/or ketone level (18/21, 86%) were the most frequently used end points to define resolution.
Conclusions
There are substantial variations in insulin regimens and resolution criteria in DKA management protocols across Australian hospitals. Clinician preference was diverse. This likely reflects the lack of high‐quality evidence to guide practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, New South Wales, Australia.
- Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
- School of Clinical Medicine, St Vincent's Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
- Department of Intensive Care, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Lisa M Raven, Jerry R Greenfield
Zitieren
APA
Raven, L. M., Lever, W., MacIsaac, R. J., Greenfield, J. R., Deane, A., Plummer, M., & Umapathysivam, M. (2025). Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey. Internal Medicine Journal. https://doi.org/10.1111/imj.70024
Vancouver
Raven LM, Lever W, MacIsaac RJ, Greenfield JR, Deane A, Plummer M, et al. Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey. Internal Medicine Journal. 2025. doi:10.1111/imj.70024
BibTeX
@article{Raven2025,
author = {Raven, Lisa M and Lever, William and MacIsaac, Richard J and Greenfield, Jerry R and Deane, Adam and Plummer, Mark and Umapathysivam, Mahesh},
title = {Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.70024}
}
EUVIMED